Where you live determines whether you will be able to access to controlled medicines, particularly opiates, when confronting an acute terminal, chronic or painful illness. Ninety-two per cent of the world's morphine is consumed by only 17% of the world's population, primarily the United States and Europe. Seventy--five percent of the world's people in need do not have access to pain relieving medicine
In other words, most of the global population, outside the affluent countries in the North, dying in pain, including from terminal cancers, do so in the absence of dignified palliative care.
This is a horrendous situation for millions of patients and families. Essential medicines such as morphine, taken for granted as the standard relief of severe pain in the global North, do not enjoy the same status in the global South. Quite the opposite. Chances are, if a person living in any developing country ends up with an illness associated with extreme and avoidable pain, they will endure the pain simply because their government has created obstacles to morphine use in hospitals.
Because of unfounded fears of addiction, doctors are hesitant to prescribe these pain relieving drugs. Additionally, people who inject drugs are often denied access to controlled medicines to treat opioid dependence, including methadone and buprenorphine.
This is unacceptable but what is more, this global crisis of pain is avoidable.
'The international drug control system is broken'
The Global Commission on Drug Policy (GCDP)
sees the problem of access to controlled medicines as a critical global issue and finds that restrictions and conditions to avoid these medicines being used for illicit purposes by international drug control bodies and national governments has caused millions of people to needlessly suffer. Because of the stigma associated with certain controlled medicines, particularly opiates, it is more difficult for health systems, doctors and hospitals to access these medicines for their patients.
According to U.N. drug control conventions, states have an obligation to properly provide these treatments to all people who require them. However, barriers such as discrimination, lack of training for clinicians, and heavy bureaucratic restrictions translate into lack of access and uncontrolled pain.
The United Nations and member states must strike a fair balance between ensuring access and preventing medical substances from entering the black market, with a clear focus on health and human rights.
The international d